All In Biotech

Drug Trial Radar · NCT02500706

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Jun 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,108

Actual

Start

May 4, 2016

Primary completion

Jul 17, 2017

Study completion Aug 16, 2017

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jul 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1

Interventions

  • Faster-acting insulin aspartDrug

    Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.

  • insulin aspartDrug

    Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.

  • insulin degludecDrug

    Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c 26 Weeks After RandomisationTime frame: Week 0, week 26

Locations

152 sites in 13 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Tucson, Arizona

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Encino, California

  • Novo Nordisk Investigational Site

    Escondido, California

  • Novo Nordisk Investigational Site

    Fresno, California

  • Novo Nordisk Investigational Site

    Fullerton, California

  • Novo Nordisk Investigational Site

    Huntington Beach, California

  • Novo Nordisk Investigational Site

    Monterey, California

  • Novo Nordisk Investigational Site

    Newport Beach, California

  • Novo Nordisk Investigational Site

    Santa Barbara, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Denver, Colorado

  • Novo Nordisk Investigational Site

    Golden, Colorado

  • Novo Nordisk Investigational Site

    Palm Harbor, Florida

  • Novo Nordisk Investigational Site

    Tampa, Florida

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Idaho Falls, Idaho

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Lexington, Kentucky

  • Novo Nordisk Investigational Site

    Louisville, Kentucky

  • Novo Nordisk Investigational Site

    Baltimore, Maryland

  • Novo Nordisk Investigational Site

    Rockville, Maryland

  • Novo Nordisk Investigational Site

    Flint, Michigan

  • Novo Nordisk Investigational Site

    Kalamazoo, Michigan

  • Novo Nordisk Investigational Site

    Minneapolis, Minnesota

  • Novo Nordisk Investigational Site

    Jefferson City, Missouri

  • Novo Nordisk Investigational Site

    Las Vegas, Nevada

  • Novo Nordisk Investigational Site

    Nashua, New Hampshire

  • Novo Nordisk Investigational Site

    Hamilton, New Jersey

  • Novo Nordisk Investigational Site

    Lawrenceville, New Jersey

  • Novo Nordisk Investigational Site

    Albuquerque, New Mexico

  • Novo Nordisk Investigational Site

    Albany, New York

  • Novo Nordisk Investigational Site

    Rochester, New York

  • Novo Nordisk Investigational Site

    Chapel Hill, North Carolina

  • Novo Nordisk Investigational Site

    Greenville, North Carolina

  • Novo Nordisk Investigational Site

    Wilmington, North Carolina

  • Novo Nordisk Investigational Site

    Bend, Oregon

  • Novo Nordisk Investigational Site

    Philadelphia, Pennsylvania

  • Novo Nordisk Investigational Site

    Chattanooga, Tennessee

  • Novo Nordisk Investigational Site

    Amarillo, Texas

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.